Pox Virus, VSV And HSV Platforms

Manufacturing viral vaccines, oncolytic therapies, and gene therapies requires more than production capacity. Success depends on choosing a partner with proven platform expertise, scalable technologies, and the analytical capabilities needed to navigate complex development and regulatory challenges. From early-stage process development through commercial supply, each step must be designed to support product quality, consistency, and speed to clinic.

Drawing on decades of experience with pox viruses, including MVA, as well as VSV and HSV platforms, IDT Biologika brings together integrated manufacturing, analytical testing, and regulatory expertise to support a broad range of viral programs. Organizations can benefit from established cell banking capabilities, freedom-to-operate platforms, flexible bioreactor technologies, and advanced quality control methods that enable efficient scale-up and process optimization. With dedicated support spanning development, GMP manufacturing, release testing, and commercialization, teams can streamline technology transfer while maintaining confidence in product quality and regulatory readiness.

Explore how platform-based expertise can help accelerate the path from concept to clinical and commercial success.